Transgene Biotek Peer Comparison

BSE: 526139

₹2.57

₹0.17 (7.08%)

As on 04-Nov-2026IST

Market cap

₹19 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

2.4

Div. Yield

0 %

Edit

	Transgene Biotek	Tarsons Products	Gland Pharma	Poly Medicure	Medplus Health
Market cap (₹ Cr)	19	1,651	52,105	16,093	7,211
Revenue (₹ Cr)	0	441	6,725	1,997	7,587
Net Profit (₹ Cr)	-1.61	11.10	1,128.79	307.01	211.00
Net Margin (%)	-431.37	2.37	16.02	14.56	2.75
RoE (%)	-16.73	1.88	11.51	10.63	10.44
Price to Earnings	--	148.83	46.16	51.07	34.17
Price-To-Book	2.44	2.61	4.90	5.06	3.49

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Transgene Biotek	Tarsons Products	Gland Pharma	Poly Medicure	Medplus Health
Operating Revenue	0.22	441.39	6,725.30	1,997.43	7,587.21
Total Income	0.37	468.21	7,045.33	2,108.80	7,666.42
Total Expenditure	0.69	322.18	4,974.15	1,536.06	6,956.12
EBITDA	-0.46	119.21	1,751.15	461.36	631.09
Depreciation	0.19	103.61	433.87	128.17	310.44
EBIT	-0.65	15.59	1,317.28	333.19	320.65
Interest	1.11	23.74	26.14	21.84	134.20
Other Income	0.15	26.82	320.03	111.37	79.21
Exceptional Items	0.00	-1.13	-24.35	-6.80	0.00
Profit before Tax	-1.61	17.54	1,586.82	415.92	265.65
Provision for Tax	0.00	6.45	458.02	108.91	54.66
Profit after Tax	-1.61	11.10	1,128.79	307.01	211.00

Liabilities (₹ Cr)

	Transgene Biotek	Tarsons Products	Gland Pharma	Poly Medicure	Medplus Health
Shareholder's Funds	9.21	634.69	10,357.95	3,106.17	2,068.28
Minority Interest	0.00	0.00	0.00	2.16	0.04
Non-Current Liabilities	121.66	286.94	544.50	193.80	1,361.51
Current Liabilities	12.88	264.19	1,608.40	575.52	768.76
Total Liabilities	144.09	--	11,172.85	3,279.77	3,456.02

Assets (₹ Cr)

	Transgene Biotek	Tarsons Products	Gland Pharma	Poly Medicure	Medplus Health
Non-Current Assets	142.73	875.11	4,858.96	1,874.17	558.11
Current Assets	1.02	265.75	7,526.79	1,941.73	2,178.89
Total Assets	144.09	--	11,172.85	3,279.77	3,456.02
Total Debt*	14.52	--	269.21	177.65	0.00
Net Current Assets	-11.86	1.56	5,918.38	1,366.21	1,410.13
Contingent Liabilities	2.58	--	21.38	77.12	13.78

Cashflow (₹ Cr)

	Transgene Biotek	Tarsons Products	Gland Pharma	Poly Medicure	Medplus Health
Cash From Operating Activities	1.20	--	914.73	233.05	540.43
Cash Flow from Investing Activities	-1.70	--	1,704.74	-1,187.18	-317.61
Cash from Financing Activities	0.78	--	-433.48	950.51	-227.98
Net Cash Inflow / Outflow	0.28	--	2,185.99	-3.63	-5.16

Ratios

Profitability Ratios

	Transgene Biotek	Tarsons Products	Gland Pharma	Poly Medicure	Medplus Health
ROCE (%)	-1.75	--	11.97	20.37	18.22
ROE (%)	-16.73	1.88	11.51	10.63	10.44
ROA (%)	-1.13	0.98	9.51	8.63	5.43
EBIT Margin (%)	-293.27	3.53	19.59	16.68	4.23
Net Margin (%)	-431.37	2.37	16.02	14.56	2.75
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Transgene Biotek	Tarsons Products	Gland Pharma	Poly Medicure	Medplus Health
Revenue Growth (%)	-14.89	10.63	17.57	18.31	20.57
EBIT Growth (%)	32.58	-65.55	33.69	-9.66	11.48
Net Profit Growth (%)	-22.92	-59.71	46.55	-12.67	8.18
EPS Growth (%)	-22.92	-57.00	48.78	-10.52	7.89
Book Value Growth (%)	-6.38	--	4.91	88.41	10.77

Valuation Ratios

	Transgene Biotek	Tarsons Products	Gland Pharma	Poly Medicure	Medplus Health
Price / Earnings	-12.10	139.47	45.40	50.27	34.13
Price / Book Value	2.44	2.61	4.90	5.06	3.49
Dividend Yield (%)	0.00	0.00	0.63	0.22	0.00
EV/EBITDA	-72.80	16.85	27.98	33.83	10.69
Market Cap (₹ Cr)	25.38	--	26,233.01	22,718.23	9,091.18

Solvency Ratios

	Transgene Biotek	Tarsons Products	Gland Pharma	Poly Medicure	Medplus Health
Debt to Equity	0.70	0.33	0.01	0.02	0.00
Short term debt to equity ratio	0.84	--	--	0.06	--
Current Ratio	0.08	1.01	4.68	3.37	2.83
Quick Ratio	0.08	0.51	3.60	2.62	0.86
Interest Coverage	-0.46	1.74	61.70	20.04	2.98

Operating Efficiency Ratios

	Transgene Biotek	Tarsons Products	Gland Pharma	Poly Medicure	Medplus Health
Debtors to sales (%)	3.59	19.35	28.12	26.59	0.51
Asset Turnover	0.00	0.39	0.57	0.56	1.95
Receivable days	11.76	--	99.92	67.43	0.90
Inventory Days	47.53	--	108.54	55.13	78.76
Payable days	--	--	138.65	74.14	21.71
Cash Conversion Cycle	--	--	69.81	48.42	57.95

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.